Podiatrists in Sayville, NY Accepting Medicare
6 Podiatrists found. Showing 1 - 6
 Dr. Thomas James Furci, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 43 Broadway Ave, Sayville, NY 11782 Phone: 631-589-8484 Fax: 631-589-8553 |
John R Trinidad, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 193 Greene Ave, Sayville, NY 11782 Phone: 631-589-1706 Fax: 631-218-1863 |
 James Paul Dinovis Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1 Neel Court, Suite A, Sayville, NY 11782 Phone: 631-563-2467 |
Dr. James Paul Dinovis, D.P.M. Podiatrist Medicare: Medicare Enrolled Practice Location: 1 Neel Ct, Suite A, Sayville, NY 11782 Phone: 631-563-2467 Fax: 631-563-3213 |
Thomas J Furci Dpm Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 43 Broadway Ave, Sayville, NY 11782 Phone: 631-589-8484 Fax: 631-589-8553 |
Brent Thomas Kempf, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 110 Lakeland Ave, Sayville, NY 11782 Phone: 631-567-2888 Fax: 631-567-2369 |
News Archive
Manchester researchers reveal why ER+ breast cancer women develop resistance to hormone therapy
University of Manchester researchers funded by Breast Cancer Now have discovered a new explanation as to why women with oestrogen receptor positive (ER+) breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem.
State rejections of Medicaid expansion likely to widen health disparities
The Los Angeles Times reports that states opting against expanded eligibility - among them, some of the nation's unhealthiest - could fall even further behind as the Affordable Care Act is implemented. News outlets also offer reports from Arizona, Michigan, Wisconsin, Ohio, California, Florida and Virginia.
Season of conception a factor in how a child does in school
According to the latest research the time of year a woman conceives may affect her child's academic performance.
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
High cardiorespiratory fitness levels reduce risk of arrhythmia recurrence in obese atrial fibrillation patients
Obese atrial fibrillation patients have a lower chance of arrhythmia recurrence if they have high levels of cardiorespiratory fitness, and risk continues to decline as exercise capacity increases as part of treatment, according to a study published today in the Journal of the American College of Cardiology.
› Verified 8 days ago
Speech-Language Pathologists
Physical Therapists
Chiropractors
Occupational Therapists
Optometrists
Podiatrists